Health News Roundup: Eli Lilly to sell low blood sugar drug to Amphastar for around $1 billion; Bluebird bio submits US marketing application for blood disorder gene therapy and more

Following is a summary of current health news briefs. Eli Lilly to sell low blood sugar drug to Amphastar for around $1 billion Amphastar Pharmaceuticals will buy Baqsimi from Eli Lilly and Co in a deal worth up to $1.08 billion as it aims to boost its portfolio of low blood sugar drugs, the two companies said on Monday.

Following is a summary of current health news briefs.

Eli Lilly to sell low blood sugar drug to Amphastar for around $1 billion

Amphastar Pharmaceuticals will buy Baqsimi from Eli Lilly and Co in a deal worth up to $1.08 billion as it aims to boost its portfolio of low blood sugar drugs, the two companies said on Monday. Amphastar will pay $500 million at closing and another $125 million in cash after one year under the deal.

Bluebird bio submits US marketing application for blood disorder gene therapy

Bluebird bio Inc said on Monday it has submitted a marketing application to the U.S. Food and Drug Administration for its gene therapy to treat sickle cell disease. The announcement comes nearly a month after the company said it would miss its goal to submit the application by the end of March for regulatory approval of lovo-cel, its gene therapy.

Foghorn Therapeutics pauses enrollment in cancer drug study

Drug developer Foghorn Therapeutics Inc said on Monday it has paused enrollment in an early-stage study of the company's experimental drug for a rare form of cancer due to safety concerns. The company said the U.S. Food and Drug Administration has also placed the study on partial hold in the United States, while allowing patients currently enrolled and benefiting from therapy to continue dosage of the drug, FHD-609.

Supreme Court preserves broad access to abortion pill

The U.S. Supreme Court on Friday blocked new restrictions set by lower courts on a widely used abortion pill, a decision welcomed by President Joe Biden as his administration defends broad access to the drug in the latest fierce legal battle over reproductive rights in the United States. The justices, in a brief order, granted emergency requests by the Justice Department and the pill's manufacturer Danco Laboratories to put on hold an April 7 preliminary injunction issued by U.S. District Judge Matthew Kacsmaryk in Texas. The judge's order would have greatly limited the availability of mifepristone while litigation proceeds in a challenge by anti-abortion groups to the pill's federal regulatory approval.